雲南白藥(000538.SZ):2021年繼續利用閒置自有資金開展證券投資
格隆匯 12 月 30日丨雲南白藥(000538.SZ)公佈,在股東大會審議通過額度和投資範圍內,2021年度公司擬繼續開展證券投資業務,投資範圍:1、風險等級為R1、R2的銀行理財產品、貨幣市場基金、國債逆回購及債券、債券型基金/資管計劃;2、混合型基金/資管計劃、股票或股權型基金/資管計劃。
投資額度:在保證日常經營運作資金需求,有效控制投資風險同時理財投資總額度不超過最近一個會計年度審計後淨資產的45%(含);其中,投資股票和股票基金、股權基金的比例,合計不得高於最近一個會計年度審計後淨資產的15%(含)。
投資額度期限:2021年1月1日至2021年12月31日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.